This number is likely to have exponentially increased with the spread of the omicron variant, the most transmissible SARS-CoV-2 variant to date, suggesting that most of the global population has now already experienced SARS-CoV-2 infection at least once. As with previous infections, vaccines induce a memory response and protection against COVID-19, and the combination of SARS-CoV-2 infection and vaccination (hybrid immunity) offers the highest rate of protection. However, the durability of this protection against reinfection and severe disease remains undefined.
present the results of a well-conducted systematic review and meta-analysis investigating the long-term benefit of SARS-CoV-2 vaccines in individuals who have developed hybrid immunity. The authors observed ephemeral protection against reinfection after booster vaccination (46·5% [36·0–57·3] at 6 months) or previous infection (24·7% [95% CI 16·4–35·5] at 12 months) but sustained high levels of protection against hospital admission or severe disease 6–12 months after the last exposure to SARS-CoV-2 antigens (97·4% [95% CI 91·4–99·2] with primary series vaccination at 12 months and 95·3% [81·9–98·9] with the first booster vaccination at 6 months). The magnitude and durability of protection was particularly high for those with hybrid immunity compared to those with previous infection alone, reinforcing the importance of vaccination despite previous infection in protecting against severe disease due to the omicron variant. There were two important findings about the primary series versus the booster dose in cases of previous infection: the primary series offered a high rate of protection (>90%) against severe disease, without imparting additional protection after booster vaccination; and both the primary series and booster vaccination offered short-term protection against reinfection. These findings align with the preserved cellular immune response despite the decrease in the humoral response to omicron subvariants.
,
Nonetheless, these findings should be interpreted with caution since the conclusions cannot be extrapolated to specific groups at increased risk of developing severe disease, such as older and immunosuppressed people, who were not analysed in this study.
clearly demonstrate that the focus of first-generation vaccines should be prevention of severe disease. For this purpose, a first-generation vaccine is still an excellent option when offered as a primary series in areas with a high rate of previous infection, or with boosters, if a low infection rate has been observed.
Even though nearly 70% of the world’s population has received at least one SARS-CoV-2 vaccine dose, the distribution of vaccine coverage remains unequal. North America has vaccinated approximately 76% of its population with one dose, while Africa has only vaccinated 32%.
High-income countries administered almost five times more doses than low-income countries for the primary series and more than 20 times more booster doses.
Coverage can be improved even in countries with high availability of vaccines. For example, in the USA only 69% of the population has completed the primary series vaccination.
This inequality of distribution between low-income and high-income countries and the relatively high refusal to receive vaccines in high-income countries still need to be addressed to achieve higher protection against hospital admission and death due to COVID-19. These strategies could include more equitable distribution of vaccines within countries and improved communication about the protection offered by hybrid immunity.
We are currently facing a new wave of omicron subvariants. While waiting for data about the effectiveness of bivalent and other next-generation vaccines, the gold standards against COVID-19 remain both non-pharmacological strategies to prevent SARS-CoV-2 infection and vaccination to avoid severe disease.
VSB and MB-N are employees of Fiocruz, a federal public institution that manufactures the ChAdOx1 (Oxford–AstraZeneca) vaccine in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health in Brazil for public health use. TC-S declares no competing interests.
References
- 1.
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
Lancet. 2022; 399: 2351-2380
- 2.
Hybrid immunity.
Science. 2021; 372: 1392-1393
- 3.
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
Lancet Infect Dis. 2023; ()
- 4.
Post-vaccination T cell immunity to omicron.
Front Immunol. 2022; 13944713
- 5.
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
Cell Host Microbe. 2022; 30: 1527-1539
- 6.
Coronavirus pandemic (COVID-19). Our World Data.
Article Info
Publication History
Published: January 18, 2023
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
